Source: Walker RF, Clinical Interventions in Aging , 2007, PMC2699646
Purpose of the article
To discuss the potential of Sermorelin as a more physiological and safer alternative to recombinant human growth hormone (rhGH) in adults with GH deficiency or age-related decrease in its secretion.
Basic information
Traditional rhGH therapy is effective in counteracting somatic aging, but it carries a number of risks:
- Incorrect dosage can cause serious side effects.
- Exogenous GH creates nonphysiological spikes (“square-wave”) that are not controlled by feedback.
- The legal framework limits the use of rhGH only to certain clinical indications (AIDS or proven GHD).
Sermorelin (GHRH 1–29 NH 2 -acetate) is an analogue of the natural GH-releasing hormone (GHRH), levels of which decline with age. By binding to receptors in the pituitary gland, it activates endogenous GH release, mimicking the physiological pulsatile response.
Main advantages over rhGH
- Physiological control: The effects are regulated by somatostatin, which prevents overdose.
- Pulsatile secretion: GH release is episodic, not a constant peak as with rhGH.
- No tachyphylaxis: Secretion remains sensitive to stimuli due to a natural rhythm of release.
- Supports pituitary function: Stimulates GH mRNA transcription and increases hormonal reserve.
- Slows down the aging of the endocrine axis: Helps maintain normal physiology with age.
Legal and clinical status
Unlike rhGH, Sermorelin has no federal restrictions on prescribing in adults, allowing clinicians to use it off-label within research protocols to evaluate its effectiveness and safety.
Conclusion
- Sermorelin offers a more physiological approach to GHRT in adults.
- Reduces the risk of side effects and supports the natural regulation of the GH/IGF-1 axis.
- It can be used as a safe and legal alternative to maintain hormonal balance during aging.
